TY - JOUR
T1 - Gut dysbiosis associated with hepatitis C virus infection
AU - Inoue, Takako
AU - Nakayama, Jiro
AU - Moriya, Kei
AU - Kawaratani, Hideto
AU - Momoda, Rie
AU - Ito, Kiyoaki
AU - Iio, Etsuko
AU - Nojiri, Shunsuke
AU - Fujiwara, Kei
AU - Yoneda, Masashi
AU - Yoshiji, Hitoshi
AU - Tanaka, Yasuhito
N1 - Funding Information:
Potential conflicts of interest. T. I. is currently supported by a research grant from Gilead Sciences. Y. T. is currently conducting research sponsored by Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Janssen Pharmaceutical K.K., AbbVie Inc., MSD K.K., and Gilead Sciences. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Funding Information:
Funding. This work was supported by a grant-in-aid from the Research Program on Hepatitis from the Japan Agency for Medical Research and Development (JP17fk0210201h0002), by the Ministry of Education, Culture, Sports, Science, and Technology (15K09015), grant support from MSD, grant-in-aid from Gilead Sciences, and grant-in-aid for research from Nagoya City University.
Publisher Copyright:
© The Author(s) 2018.
PY - 2018/8/31
Y1 - 2018/8/31
N2 - Background. Little is known about the effect of hepatitis C virus (HCV) infection on gut microbiota and the relationship between alteration of gut microbiota and chronic hepatitis C (CHC) progression. We performed a comparative study of gut microbiota composition between CHC patients and healthy individuals. Methods. Fecal samples from 166 CHC patients were compared with those from 23 healthy individuals; the gut microbiota community was analyzed using 16S ribosomal RNA gene sequencing. CHC patients were diagnosed with persistently normal serum alanine aminotransferase without evidence of liver cirrhosis (LC) (PNALT, n = 18), chronic hepatitis (CH, n = 84), LC (n = 40), and hepatocellular carcinoma in LC (n = 24). Results. Compared with healthy individuals, bacterial diversity was lower in persons with HCV infection, with a decrease in the order Clostridiales and an increase in Streptococcus and Lactobacillus. Microbiota dysbiosis already appeared in the PNALT stage with the transient increase in Bacteroides and Enterobacteriaceae. Predicted metagenomics of microbial communities showed an increase in the urease gene mainly encoded by viridans streptococci during CHC progression, consistent with a significantly higher fecal pH in CH and LC patients than in healthy individuals or those in the PNALT stage. Conclusions. HCV infection is associated with gut dysbiosis, even in patients with mild liver disease. Additionally, overgrowth of viridans streptococci can account for hyperammonemia in CH and LC. Further studies would help to propose a novel treatment strategy because the gut microbiome can be therapeutically altered, potentially reducing the complications of chronic liver disease.
AB - Background. Little is known about the effect of hepatitis C virus (HCV) infection on gut microbiota and the relationship between alteration of gut microbiota and chronic hepatitis C (CHC) progression. We performed a comparative study of gut microbiota composition between CHC patients and healthy individuals. Methods. Fecal samples from 166 CHC patients were compared with those from 23 healthy individuals; the gut microbiota community was analyzed using 16S ribosomal RNA gene sequencing. CHC patients were diagnosed with persistently normal serum alanine aminotransferase without evidence of liver cirrhosis (LC) (PNALT, n = 18), chronic hepatitis (CH, n = 84), LC (n = 40), and hepatocellular carcinoma in LC (n = 24). Results. Compared with healthy individuals, bacterial diversity was lower in persons with HCV infection, with a decrease in the order Clostridiales and an increase in Streptococcus and Lactobacillus. Microbiota dysbiosis already appeared in the PNALT stage with the transient increase in Bacteroides and Enterobacteriaceae. Predicted metagenomics of microbial communities showed an increase in the urease gene mainly encoded by viridans streptococci during CHC progression, consistent with a significantly higher fecal pH in CH and LC patients than in healthy individuals or those in the PNALT stage. Conclusions. HCV infection is associated with gut dysbiosis, even in patients with mild liver disease. Additionally, overgrowth of viridans streptococci can account for hyperammonemia in CH and LC. Further studies would help to propose a novel treatment strategy because the gut microbiome can be therapeutically altered, potentially reducing the complications of chronic liver disease.
UR - http://www.scopus.com/inward/record.url?scp=85051627565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051627565&partnerID=8YFLogxK
U2 - 10.1093/cid/ciy205
DO - 10.1093/cid/ciy205
M3 - Article
C2 - 29718124
AN - SCOPUS:85051627565
SN - 1058-4838
VL - 67
SP - 869
EP - 877
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 6
ER -